TY - JOUR
T1 - Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer
T2 - A Case Series
AU - Iravani, Amir
AU - Mitchell, Catherine
AU - Akhurst, Tim
AU - Sandhu, Shahneen
AU - Hofman, Michael S.
AU - Hicks, Rodney J.
N1 - Funding Information:
We appreciate the outstanding efforts and collaboration of the entire urology–oncology multidisciplinary and nuclear medicine team at Peter MacCallum Cancer Centre. RJH is the recipient of a National Health and Medical Research Council Practitioner Fellowship (APP1108050). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have stated that they have no conflicts of interest.
Funding Information:
RJH is the recipient of a National Health and Medical Research Council Practitioner Fellowship (APP1108050). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have stated that they have no conflicts of interest.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/8
Y1 - 2021/8
N2 - • Molecular imaging targeting the prostate-specific membrane antigen, somatostatin receptor subtype 2, and glycolytic pathway may further enhance our understanding of the heterogeneity of the neuroendocrine differentiation of prostate cancer in a non-invasive manner and on a whole-body scale. • Molecular imaging heterogeneity of the neuroendocrine differentiation of prostate cancer may have important implications on the selection of patients for radionuclide therapy. • Coexisting neuroendocrine differentiation of prostate cancer and adenocarcinoma of the prostate within one biopsy sample or across a patient further supports the use of molecular imaging to verify the biologic target expression on a whole-body scale.
AB - • Molecular imaging targeting the prostate-specific membrane antigen, somatostatin receptor subtype 2, and glycolytic pathway may further enhance our understanding of the heterogeneity of the neuroendocrine differentiation of prostate cancer in a non-invasive manner and on a whole-body scale. • Molecular imaging heterogeneity of the neuroendocrine differentiation of prostate cancer may have important implications on the selection of patients for radionuclide therapy. • Coexisting neuroendocrine differentiation of prostate cancer and adenocarcinoma of the prostate within one biopsy sample or across a patient further supports the use of molecular imaging to verify the biologic target expression on a whole-body scale.
KW - Fluorodeoxyglucose
KW - Neuroedocrine differentiation of prostate cancer
KW - Prostate-specific membrane antigen
KW - Radionuclide therapy
KW - Somatostatin receptor
UR - http://www.scopus.com/inward/record.url?scp=85102042211&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2021.01.008
DO - 10.1016/j.clgc.2021.01.008
M3 - Article
C2 - 33678552
AN - SCOPUS:85102042211
SN - 1558-7673
VL - 19
SP - e200-e205
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 4
ER -